Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies.

[1]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[2]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[3]  Michel Sadelain,et al.  The basic principles of chimeric antigen receptor design. , 2013, Cancer discovery.

[4]  M. Peppelenbosch,et al.  Activated tumor‐infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer , 2013, Hepatology.

[5]  Youping Deng,et al.  Effect of Pemetrexed on Innate Immune Killer Cells and Adaptive Immune T Cells in Subjects With Adenocarcinoma of the Pancreas , 2012, Journal of immunotherapy.

[6]  H. Abken,et al.  T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. , 2012, Gastroenterology.

[7]  Huamin Wang,et al.  Overexpressed Galectin-3 in Pancreatic Cancer Induces Cell Proliferation and Invasion by Binding Ras and Activating Ras Signaling , 2012, PloS one.

[8]  J. Willmann,et al.  Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma , 2012, Cancer biology & therapy.

[9]  S. Goerdt,et al.  Differentiation and gene expression profile of tumor-associated macrophages. , 2012, Seminars in cancer biology.

[10]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[11]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[12]  F. Harrell,et al.  A randomized, placebo-controlled, double blind, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gem versus gem alone in patients with resected pancreas cancer with activating RAS mutations/survival and immunology analysis of the R1 subgroup. , 2012 .

[13]  Y. Miao,et al.  High expression of Galectin‐1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer , 2012, International journal of cancer.

[14]  B. Neyns,et al.  Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  Kanji Takahashi,et al.  Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection. , 2012, The Journal of surgical research.

[16]  H. Toyokawa,et al.  Circulating CD4+CD25+ Regulatory T Cells in Patients With Pancreatic Cancer , 2012, Pancreas.

[17]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[18]  Min Shi,et al.  Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. , 2012, World journal of gastroenterology.

[19]  R. Ni,et al.  The expressions and clinical significances of tissue and serum galectin-3 in pancreatic carcinoma , 2012, Journal of Cancer Research and Clinical Oncology.

[20]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[21]  D. Stocken,et al.  Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13 , 2011, Cancer Immunology, Immunotherapy.

[22]  G. Abou-Alfa,et al.  Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine , 2011, American journal of clinical oncology.

[23]  Kejing Zhang,et al.  Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer , 2011, Medical oncology.

[24]  S. Natsugoe,et al.  Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. , 2011, The Journal of surgical research.

[25]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[26]  G. Gaudernack,et al.  Long‐term follow‐up of patients with resected pancreatic cancer following vaccination against mutant K‐ras , 2011, International journal of cancer.

[27]  S. Kondo,et al.  The CD40‐CD154 interaction would correlate with proliferation and immune escape in pancreatic ductal adenocarcinoma , 2011, Journal of surgical oncology.

[28]  K. Lillemoe,et al.  A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation , 2011, Annals of surgery.

[29]  Egbert Oosterwijk,et al.  Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. , 2011, Blood.

[30]  D. Kranz.  Faculty Opinions recommendation of Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. , 2010 .

[31]  James O. Jones,et al.  Suppression of Antitumor Immunity by Stromal Cells Expressing , 2022 .

[32]  M. Larsson,et al.  Semi Mature Blood Dendritic Cells Exist in Patients with Ductal Pancreatic Adenocarcinoma Owing to Inflammatory Factors Released from the Tumor , 2010, PloS one.

[33]  S. Rosenberg,et al.  Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.

[34]  S. Maehara,et al.  Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry. , 2010, Anticancer research.

[35]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[36]  David H. Lee,et al.  Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells , 2010, The Journal of Immunology.

[37]  Y. Chiang,et al.  Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  S. Ostrand-Rosenberg.  Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity , 2010, Cancer Immunology, Immunotherapy.

[39]  Peter Olson,et al.  Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. , 2010, Cancer cell.

[40]  Min Zhang,et al.  Clinical Significance of B7-H1 and B7-1 Expressions in Pancreatic Carcinoma , 2010, World Journal of Surgery.

[41]  H. Friess,et al.  Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer , 2009, BMC Cancer.

[42]  K. Shimada,et al.  Clinical importance of B7-H3 expression in human pancreatic cancer , 2009, British Journal of Cancer.

[43]  M. Manns,et al.  Increase in frequency of myeloid‐derived suppressor cells in mice with spontaneous pancreatic carcinoma , 2009, Immunology.

[44]  R. Vonderheide,et al.  Clinical Use of Anti‐CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells , 2009, Annals of the New York Academy of Sciences.

[45]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[46]  J. Nemunaitis,et al.  A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  G. Kuttan,et al.  Role of macrophages in tumour progression. , 2009, Immunology letters.

[48]  F. Qin,et al.  Dynamic Behavior and Function of Foxp3+ Regulatory T Cells in Tumor Bearing Host , 2009, Cellular and Molecular Immunology.

[49]  I. C. Leão,et al.  Effective Depletion of Regulatory T Cells Allows the Recruitment of Mesothelin‐Specific CD8+ T Cells to the Antitumor Immune Response Against a Mesothelin‐Expressing Mouse Pancreatic Adenocarcinoma , 2008, Clinical and translational science.

[50]  M. Braga,et al.  Carcinoembryonic Antigen-Specific but Not Antiviral CD4+ T Cell Immunity Is Impaired in Pancreatic Carcinoma Patients1 , 2008, The Journal of Immunology.

[51]  Helen Y Wang,et al.  Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. , 2008, Cancer research.

[52]  M. Oka,et al.  Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. , 2008, Oncology reports.

[53]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[54]  C. Yeo,et al.  Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. , 2008, Journal of the American College of Surgeons.

[55]  S. Choi,et al.  PROTEOMIC ANALYSIS TO IDENTIFY BIOMARKER PROTEINS IN PANCREATIC DUCTAL ADENOCARCINOMA , 2008, ANZ journal of surgery.

[56]  Shusen Zheng,et al.  B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression , 2008, Journal of Cancer Research and Clinical Oncology.

[57]  K. McMasters,et al.  Transient T cell depletion causes regression of melanoma metastases , 2008, Journal of Translational Medicine.

[58]  C. Pilarsky,et al.  Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. , 2007, Cancer research.

[59]  H. Pandha,et al.  Loss of expression of antigen‐presenting molecules in human pancreatic cancer and pancreatic cancer cell lines , 2007, Clinical and experimental immunology.

[60]  M. Azuma,et al.  Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer , 2007, Clinical Cancer Research.

[61]  Haidong Dong,et al.  Costimulation, coinhibition and cancer. , 2007, Current cancer drug targets.

[62]  Y. Morine,et al.  Clinical Roles of Increased Populations of Foxp3+CD4+ T Cells in Peripheral Blood from Advanced Pancreatic Cancer Patients , 2006, Pancreas.

[63]  G. Gaudernack,et al.  Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study , 2006, British Journal of Cancer.

[64]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[65]  S. Hirohashi,et al.  Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions , 2006, Clinical Cancer Research.

[66]  U. Grohmann,et al.  The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1 , 2006, The Journal of Immunology.

[67]  M. Pirisi,et al.  Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival , 2006, Cancer Immunology, Immunotherapy.

[68]  E. Gilboa,et al.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.

[69]  S. Rosenberg,et al.  Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma , 2005, Journal of immunotherapy.

[70]  M. Büchler,et al.  High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. , 2005, Cancer research.

[71]  R. Jaster,et al.  Galectin-1 is an inductor of pancreatic stellate cell activation. , 2005, Cellular signalling.

[72]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[73]  S. Rosenberg,et al.  Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[74]  N. Funel,et al.  Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma , 2004, Journal of Clinical Pathology.

[75]  T. Oshikiri,et al.  CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma , 2004, Pancreas.

[76]  M. Ohira,et al.  TGF-beta1 promotes liver metastasis of pancreatic cancer by modulating the capacity of cellular invasion. , 2001, International journal of oncology.

[77]  G Bellone,et al.  Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. , 1999, The American journal of pathology.

[78]  H. Verspaget,et al.  Natural killer cell activity in patients with adenocarcinoma in the upper gastrointestinal tract. , 1991, Journal of clinical & laboratory immunology.

[79]  David C. Smith,et al.  Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  G. Rabinovich,et al.  Multiple functional targets of the immunoregulatory activity of galectin-1: Control of immune cell trafficking, dendritic cell physiology, and T-cell fate. , 2010, Methods in enzymology.

[81]  M. Oka,et al.  Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. , 2008, Anticancer research.

[82]  A. Moser,et al.  A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. , 2008, Cancer therapy.

[83]  M. Yashiro,et al.  TGF-beta1 down-regulates ICAM-1 expression and enhances liver metastasis of pancreatic cancer. , 2006, Advances in medical sciences.

[84]  Kohzoh Imai,et al.  Circulating anti‐MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer , 2003, International journal of cancer.

[85]  L. Grochow,et al.  Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.